Multiple Myeloma News
Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading
Pomalyst Approved for Advanced Multiple Myeloma (March 13, 2013)The U.S. Food and Drug Administration (FDA) has approved Pomalyst® (pomalidomide) for the treatment of patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. Multiple myeloma is a cancer of plasma cells,... Continue Reading
Cancer Deaths on the Decline (February 11, 2013)Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading
Zevalin Effective in Relapsed/Refractory Follicular Lymphoma (January 11, 2013)Pomalidomide plus low-dose dexamethasone (LoDEX) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone (HiDEX) in patients with refractory multiple myeloma, according to the results of a phase III... Continue Reading
Pomalidomide Improves Survival in Refractory Multiple Myeloma (January 8, 2013)Pomalidomide plus low-dose dexamethasone (LoDEX) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone (HiDEX) in patients with refractory multiple myeloma, according to the results of a phase III... Continue Reading
MLN9708 “Oral Velcade” Shows Promise in Multiple Myeloma (January 3, 2013)The investigational, oral proteasome inhibitor MLN9708, which is a new version of Velcade® (bortezomib)—may be more effective and better tolerated than the Velcade injections, according to data from a mid-stage study presented at the 54th Annual Meeting... Continue Reading
Velcade Effective for Induction and Maintenance Treatment of Multiple Myeloma (September 7, 2012)Velcade® (bortezomib) during induction and maintenance treatment improves survival in newly diagnosed stage II or III multiple myeloma, according to the results of a study published in the Journal of Clinical Oncology. Multiple myeloma is a cancer of... Continue Reading
Kyprolis Approved for Multiple Myeloma (July 24, 2012)The U.S. Food and Drug Administration (FDA) has approved Kyprolis™ (carfilzomib) for the treatment of patients with multiple myeloma that has already been treated with at least two prior therapies—including Velcade® (bortezomib) and a drug such as... Continue Reading
Three Studies Show Revlimid Provides Benefits—and Risks—in Multiple Myeloma (May 18, 2012)Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Three Studies Show Revlimid Provides Benefits—and Risks—in Multiple Myeloma (May 18, 2012)Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Latest Multiple Myeloma News By Stage
Recurrent Multiple Myeloma
Pomalyst Approved for Advanced Multiple Myeloma (March 13, 2013)
The U.S. Food and Drug Administration (FDA) has approved Pomalyst® (pomalidomide) for the treatment of patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. Multiple myeloma is a cancer of plasma cells,... Continue Reading
Zevalin Effective in Relapsed/Refractory Follicular Lymphoma (January 11, 2013)Pomalidomide plus low-dose dexamethasone (LoDEX) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone (HiDEX) in patients with refractory multiple myeloma, according to the results of a phase III... Continue Reading
Pomalidomide Improves Survival in Refractory Multiple Myeloma (January 8, 2013)Pomalidomide plus low-dose dexamethasone (LoDEX) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone (HiDEX) in patients with refractory multiple myeloma, according to the results of a phase III... Continue Reading
MLN9708 “Oral Velcade” Shows Promise in Multiple Myeloma (January 3, 2013)The investigational, oral proteasome inhibitor MLN9708, which is a new version of Velcade® (bortezomib)—may be more effective and better tolerated than the Velcade injections, according to data from a mid-stage study presented at the 54th Annual Meeting... Continue Reading
Kyprolis Approved for Multiple Myeloma (July 24, 2012)The U.S. Food and Drug Administration (FDA) has approved Kyprolis™ (carfilzomib) for the treatment of patients with multiple myeloma that has already been treated with at least two prior therapies—including Velcade® (bortezomib) and a drug such as... Continue Reading
More Recurrent Multiple MyelomaStage I/Smoldering Myeloma Multiple Myeloma
Continuous Revlimid May Improve Outcomes in Newly Diagnosed Multiple Myeloma (December 15, 2010)
Among older patients with newly diagnosed multiple myeloma, treatment with Revlimid® (lenalidomide) in combination with melphalan and prednisone, followed by Revlimid maintenance therapy (MPR-R) may result in better progression-free survival than two... Continue Reading
Revlimid Maintenance Slows Myeloma Progression After Stem Cell Transplant (December 14, 2010)Maintenance therapy with Revlimid® (lenalidomide) reduced the risk of myeloma progression or death by 60% among patients who had undergone an autologous stem cell transplant. These updated results from a Phase III clinical trial were presented at the... Continue Reading
Improved Survival with Zometa in Multiple Myeloma (December 14, 2010)It appears that treatment of patients with newly diagnosed multiple myeloma with Zometa® (zoledronic acid) may improve overall survival and progression-free survival. These findings were recently reported in The Lancet. Multiple myeloma is a cancer of... Continue Reading
Combination of Velcade and Revlimid Promising Against Newly Diagnosed Multiple Myeloma (October 29, 2010)Among patients with symptomatic newly diagnosed multiple myeloma, treatment with a combination of Revlimid® (lenalidomide), Velcade® (bortezomib), and dexamethasone produced a partial response or better in 100% of patients. The results of this Phase... Continue Reading
Denosumab More Effective Than Zometa at Delaying Bone Complications (October 15, 2010)Among patients with multiple myeloma or bone metastases from breast cancer, prostate cancer, or other solid tumors, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from... Continue Reading
More Stage I/Smoldering Myeloma Multiple MyelomaStages II-III Multiple Myeloma
Zevalin Effective in Relapsed/Refractory Follicular Lymphoma (January 11, 2013)
Pomalidomide plus low-dose dexamethasone (LoDEX) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone (HiDEX) in patients with refractory multiple myeloma, according to the results of a phase III... Continue Reading
Pomalidomide Improves Survival in Refractory Multiple Myeloma (January 8, 2013)Pomalidomide plus low-dose dexamethasone (LoDEX) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone (HiDEX) in patients with refractory multiple myeloma, according to the results of a phase III... Continue Reading
MLN9708 “Oral Velcade” Shows Promise in Multiple Myeloma (January 3, 2013)The investigational, oral proteasome inhibitor MLN9708, which is a new version of Velcade® (bortezomib)—may be more effective and better tolerated than the Velcade injections, according to data from a mid-stage study presented at the 54th Annual Meeting... Continue Reading
Velcade Effective for Induction and Maintenance Treatment of Multiple Myeloma (September 7, 2012)Velcade® (bortezomib) during induction and maintenance treatment improves survival in newly diagnosed stage II or III multiple myeloma, according to the results of a study published in the Journal of Clinical Oncology. Multiple myeloma is a cancer of... Continue Reading
Three Studies Show Revlimid Provides Benefits—and Risks—in Multiple Myeloma (May 18, 2012)Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
More Stages II-III Multiple Myeloma